Slide 1: Exchange filing cover letter for Q3 FY25 earnings call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/SG/2024-25/167 January 31, 2025 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of C
Slide 2: Q3 FY25 Earnings Call - The Multiplier Effect
Biocon Limited Q3 FY25 Earnings Call 31 - JANUARY - 2 0 2 5 The Multiplier Effect MAXIMIZING VALUE
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements made during the call concerning the future growth prospects of the Company may be forward-looking statements, which are subject to number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in s
Slide 4: Group CEO Opening Remarks
Group CEO Opening Remarks
Slide 5: Opening Remarks: Q3 FY25 Performance Overview
Opening Remarks: Q3 FY25 Performance Overview Q3 has been important and progressive reflecting both continued executional delivery and strategic strengthening across the G roup companies Highlights: Successful closure of FDA audits across multiple Biocon and Biocon Biologics sites Receipt of key pro
Slide 6: Financial Highlights
Financial Highlights
Slide 7: Financial Highlights – Q3 FY25
Financial Highlights – Q3 FY25 In ₹ Cr Q3 FY25 Q3 FY24 Q2 FY25 YoY% YoY% QoQ% (Adj.) Generics 686 703 624 (2) (2) 10 Biosimilars 2,289 2,483 2,182 (8) 141 5 Research Services 944 854 891 11 11 6 Revenue from Operations 3,821 3,954 3,590 (3) 101 6 Total Revenue 3,856 4,519 3,623 (15) 71.2 6 Core EBIT
Slide 8: Generics
Generics
Slide 9: Biocon Generics: Q3 FY25 Business Performance update
Biocon Generics: Q3 FY25 Business Performance update Sequential revenue growth of 10% driven by higher API sales and improved contribution from generic formulations Q3 Q3 Q2 In ₹ Cr YoY% QoQ% FY25 FY24 FY25 Strategic R&D investments in peptides and other complex products to Revenue from fuel mid to
Slide 10: Biosimilars
Biosimilars
Slide 11: Biocon Biologics: Q3 FY25 Business Performance Update
Biocon Biologics: Q3 FY25 Business Performance Update Strong performance in the U.S., with market shares >20% for the oncology portfolio and mid-to-high-teens for the Glargine franchise Market shares in Europe remain stable with a strong performance in key markets e.g. Germany and France where we ho
Slide 12: Biocon Biologics: Q3 FY25 Financial & Regulatory Update
Biocon Biologics: Q3 FY25 Financial & Regulatory Update Financial Performance Q3 Q3 Q2 YoY% QoQ In ₹ Cr YoY% FY25 FY24 FY25 (Adj.)1 % Revenue grew 14% vs. last year on a like-to-like basis1 while EBITDA grew 44%1 after adjusting for forex impact Revenue from 2,289 2,4832 2,182 -8% 14% 5% Operations
Slide 13: Research Services
Research Services
Slide 14: Syngene: Q3 FY25 update
Syngene: Q3 FY25 update Q3 Q3 Q2 In ₹ Cr YoY% QoQ% Broad based growth, signaling a return to growth across all divisions FY25 FY24 FY25 Discovery Services contributed to growth: Revenue from 944 854 891 11 6 Operations Continued collaborations with many large and mid-size pharma companies on pilot p
Slide 15: Concluding Remarks
‘ is cS & * | 7 he Concluding
Slide 16: Concluding Remarks: Q3 FY25
Concluding Remarks: Q3 FY25 Q3 FY25 has been important and progressive for the Biocon Group Improved growth visibility across all the businesses Maintain our outlook for a transition to growth in the second half of this fiscal year, and into the next fiscal Syngene has returned to growth, on the rig
Slide 17: Q&A - The Multiplier Effect
Q&A The Multiplier Effect MAXIMIZING VALUE